Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Could Trump’s NAFTA Renegotiation Hit Canadian Drug Price Controls?

Executive Summary

Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.

Advertisement

Related Content

Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
PhRMA Lists NAFTA Renegotiation Priorities For Better US Exports
Canada Plans Drug Price Reductions By Changing Reference Country List
Pharma Patents Are Vulnerable In Canada As Lilly Loses NAFTA Challenge
Carrots and Stick: Biopharma At The White House

Topics

Advertisement
UsernamePublicRestriction

Register

PS120937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel